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Gene expression of INPP5F as an independent prognostic
marker in fludarabine-based therapy of chronic lymphocytic
leukemia
G Palermo1, D Maisel2, M Barrett3, H Smith4, G Duchateau-Nguyen1, T Nguyen1, R-F Yeh5, A Dufour6, T Robak7, D Dornan8 and
M Weisser2 on behalf of the REACH investigators
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease. Various disease-related and patient-related factors have been
shown to influence the course of the disease. The aim of this study was to identify novel biomarkers of significant clinical relevance.
Pretreatment CD19-separated lymphocytes (n= 237; discovery set) and peripheral blood mononuclear cells (n= 92; validation set)
from the REACH trial, a randomized phase III trial in relapsed CLL comparing rituximab plus fludarabine plus cyclophosphamide
with fludarabine plus cyclophosphamide alone, underwent gene expression profiling. By using Cox regression survival analysis on
the discovery set, we identified inositol polyphosphate-5-phosphatase F (INPP5F) as a prognostic factor for progression-free survival
(Po0.001; hazard ratio (HR), 1.63; 95% confidence interval (CI), 1.35–1.98) and overall survival (Po0.001; HR, 1.47; 95% CI, 1.18–
1.84), regardless of adjusting for known prognostic factors. These findings were confirmed on the validation set, suggesting that
INPP5F may serve as a novel, easy-to-assess future prognostic biomarker for fludarabine-based therapy in CLL.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is generally an incurable
disease. However, the clinical course of the disease is hetero-
geneous. Although some patients experience rapid progression
and rapid need of antileukemic therapy, others remain stable and
are observed for many years. This heterogeneity is also reflected in
the response to therapy and in long-term clinical outcomes such
as progression-free survival (PFS) and overall survival (OS).
Prognostic factors that influence patient outcomes consist of
cytogenetic rearrangements such as del(17p) and del(11q),
molecular factors such as the immunoglobulin variable region
heavy chain (IGVH) mutational status, p53 mutational status and
expression of cell surface markers such as CD38 and ZAP70.1
Clinical factors such as age, stage of disease and lymphocyte
doubling time have also been shown to have prognostic
relevance.2 For patients in need of therapy, chemo-
immunotherapy such as the combination of fludarabine and
cyclophosphamide with the anti-CD20 monoclonal antibody
rituximab (R-FC) has been demonstrated to significantly prolong
PFS and OS compared with the combination of fludarabine and
cyclophosphamide alone (FC) in untreated (first-line) patients3 as
well as to improve PFS in previously treated (second-line)
patients.4 The objective of this study was to evaluate prognostic
and/or predictive biomarkers for rituximab-based therapy from
the REACH trial. Recently, we reported that higher expression
levels of PTK2 mRNA were associated with improved PFS in
patients treated with R-FC compared with FC alone, whereas no
significant differences were observed between the two treatment
arms in patients with lower PTK2 expression levels,5 demonstrating
predictive significance for rituximab-based chemoimmunotherapy.
Here, we demonstrate the prognostic relevance of inositol
polyphosphate-5-phosphatase F (INPP5F) gene expression, a novel,
easily assessable biomarker in relapsed CLL.
MATERIALS AND METHODS
REACH (NCT0090051) was an open-label randomized (1:1) phase III trial in
relapsed CLL comparing FC with R-FC. The primary end point of the study
was to demonstrate prolonged PFS of R-FC compared with FC alone. The
study protocol was approved by institutional review boards at participat-
ing centers and all patients gave written informed consent. Details on trial
design and eligibility criteria and clinical outcome have been described
previously.4 Patients were selected based on the availability of sufficient
RNA and had to provide written informed consent to participate in the
additional studies.
Gene expression profiling
Pretreatment samples for molecular profiling analysis were available from
237 of 552 (55%) patients enrolled in the REACH trial, selected by the
availability of adequate quality and quantity of RNA and on whether the
patients gave their informed consent to further molecular analysis.
Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll
density gradient centrifugation. CLL samples were positively enriched by
magnetic cell sorting using CD19 microbeads and MACS columns (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) and resuspended in RLT buffer
(Qiagen, Crawley, West Sussex, UK). In addition, as a validation set, PBMC
samples (n=92) were processed into RLT buffer without CD19 enrichment.
RNA from both sets was subsequently isolated using Ambion miRVANA
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total RNA extraction kit (Life Technologies, Carlsbad, CA, USA). Gene
expression profiling was performed using Affymetrix U133 Plus 2.0 full
transcriptome oligonucleotide arrays according to the manufacture-
recommended protocol (Affymetrix, Santa Clara, CA, USA).
Expression-level computations
The probe intensities of mRNA HG-U133 Plus 2.0 array were background-
subtracted, quantile-normalized and summarized using the RMA method6
within each sample type (CD19+ and PBMCs). Data were further normalized
by an empirical Bayes approach (Combat)7 to remove potential batch
effects due to data acquisition. All data used in this work were log2
transformed. Probe sets with very low expression (log2-transformed
expression levels o4.0 in 495% of samples) were excluded and a total
of 26 453 probe sets (out of 54 675) were considered for further analysis.
Statistical analysis
To test for a possible selection bias on the baseline patient characteristics
for each mRNA subset (CD19+ and PBMCs) as compared with the overall
REACH population, the χ2 test or Wilcoxon–Mann–Whitney test was used
respectively for binary and continuous variables. Similar statistical tests
were used to check whether the baseline patient characteristics were
balanced between FC and R-FC within each mRNA subset. The predictive
and/or prognostic utility of the mRNA was assessed using the following
approach. First, a log-likelihood ratio test (with two degrees of freedom
(2 d.f.)) was used to compare the Cox proportional hazards model of PFS
including treatment, mRNA (as continuous) and treatment–mRNA interac-
tion as covariates (full model) against the same model but with the
interaction term being absent (reduced model). Use of a join test (2 d.f.)
allowed simultaneous searching for both prognostic and predictive
markers, significantly increasing the power to detect predictive markers
compared with a 1-d.f. treatment–mRNA pure interaction test (based on
simulations; data not shown). The q-values (false discovery rate)8 were
calculated from raw log-likelihood ratio test P-values to account for
multiple hypothesis testing and only mRNAs with a q-value o1% were
considered significant. At this stage, the full model was considered again
and the treatment–mRNA interaction term was tested to decide whether a
significant marker was predictive or prognostic. In addition, to assess
whether candidate mRNAs provide predictive or prognostic information
independently of known prognostic factors, the mRNA was also evaluated
in the context of an expanded, multivariate Cox proportional hazards
model that included a parsimonious set of known prognostic factors
chosen (using a forward stepwise selection procedure) among the
following variables: age; Binet stage; IGVH mutational status; chromosome
17p, 11q and 13q deletions; trisomy 12; β2-microgloblulin; lymphocytic
count; and Eastern Cooperative Oncology Group (ECOG) performance
status.
All analyses were conducted using R (http://www.r-project.org).
RESULTS
Patient characteristics
Gene expression profiling data were available from 237 CD19-
enriched samples (CD19+ discovery set: 115 within the FC arm;
122 within the R-FC arm) and 92 PBMC samples that were not
enriched for CD19 (PBMC validation set: 46 within the FC arm; 46
within the R-FC arm) of 552 patients enrolled in the REACH trial.
The baseline patient demographics and tumor characteristics are
shown in Table 1 for the overall REACH population, as well as for
the CD19+ and PBMC subpopulations with available mRNA (mRNA
study population). Summaries from the table suggest that the
mRNA study population was representative of the REACH overall
study population4 (formal statistical tests for each variable in
Table 1 did not show any statistical difference between either
CD19+ or PBMC mRNA subsets as compared with the overall
population) and that the two treatment arms were well balanced
with respect to related risk factors, such as age, stage, high-risk
cytogenetics and IGVH mutational status (again there were no
statistically significant differences between FC and R-FC arm
within each mRNA subset). In addition, in the mRNA study
population, the treatment benefit with respect to PFS (CD19+:
hazard ratio (HR), 0.69; 95% confidence interval (CI), 0.47–0.99;
P= 0.046; PBMCs: HR, 0.73; 95% CI, 0.42–1.27; P= 0.26) was
comparable with that in the overall population (HR, 0.64; 95%
CI, 0.5–0.81; Po0.001) as a result of a multivariate Cox regression
model adjusting for age, Binet stage, IGVH mutational status,
ECOG performance status and del(17p). The median follow-up
Table 1. Patient characteristics
Characteristic All patients Patients with CD19+-separated mRNA data Patients with PBMC-isolated mRNA
Total R-FC FC Total R-FC FC Total R-FC FC
Sex, n (%) (n= 552) (n= 276) (n= 276) (n= 237) (n= 122) (n= 115) (n= 92) (n= 46) (n= 46)
Female 184 (33) 89 (32) 95 (34) 81 (34) 38 (31) 43 (37) 34 (37) 16 (35) 18 (39)
Male 368 (67) 187 (68) 181 (66) 156 (66) 84 (69) 72 (63) 58 (63) 30 (65) 28 (60)
Age, years (n= 552) (n= 276) (n= 276) (n= 237) (n= 122) (n= 115) (n= 92) (n= 46) (n= 46)
Mean (s.d.) 62 (9) 62 (9) 61 (9) 62 (9) 62 (9) 62 (8) 61 (8) 62 (8) 60 (9)
Median (range) 63 (35–83) 63 (35–83) 62 (35–81) 63 (35–83) 63 (35–83) 63 (37–80) 62 (39–81) 63 (39–77) 58 (44–81)
Race, n, (%) (n= 552) (n= 276) (n= 276) (n= 237) (n= 122) (n= 115) (n= 92) (n= 46) (n= 46)
Caucasian 544 (99) 271 (98) 273 (99) 233 (98) 121 (99) 112 (97) 91 (99) 45 (98) 46 (100)
Binet stage, n (%) (n= 552) (n= 276) (n= 276) (n= 237) (n= 122) (n= 115) (n= 92) (n= 46) (n= 46)
A 55 (10) 24 (9) 31 (11) 26 (11) 14 (11.5) 12 (10) 8 (9) 4 (9) 4 (9)
B 326 (59) 166 (60) 160 (58) 145 (61) 73 (60) 72 (63) 54 (59) 26 (56.5) 28 (61)
C 171 (31) 86 (31) 85 (31) 66 (28) 35 (29) 31 (27) 30 (33) 16 (35) 14 (30)
IGVH mutational status, n (%) (n= 520) (n= 258) (n= 262) (n= 235) (n= 120) (n= 115) (n= 88) (n= 42) (n= 46)
Mutated 192 (37) 100 (39) 92 (35) 91 (38) 51 (42) 40 (35) 34 (39) 16 (38) 18 (39)
Unmutated 328 (63) 158 (61) 170 (65) 144 (62) 69 (58) 75 (65) 54 (61) 26 (62) 28 (61)
Del(17p), n (%) (n= 532) (n= 269) (n= 263) (n= 235) (n= 121) (n= 114) (n= 91) (n= 46) (n= 45)
No 490 (92) 251 (93) 239 (91) 216 (92) 113 (93) 103 (90) 84 (92) 43 (93.5) 41 (91)
Yes 42 (8) 18 (7) 24 (9) 19 (8) 8 (7) 11 (10) 7 (8) 3 (6.5) 4 (9)
Abbreviations: FC, fludarabine and cyclophosphamide; IGVH, immunoglobulin variable region heavy chain; PBMC, peripheral blood mononuclear cell; R-FC,
rituximab plus fludarabine and cyclophosphamide.
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time for PFS for the CD19+ and PBMC subpopulations was 23 and
33 months, respectively. The median follow-up time for OS for the
CD19+ and PBMC subpopulations was 51 and 57 months,
respectively.
INPP5F expression and PFS
By using the statistical approach described in the Statistical
analysis section, applied to the discovery set only (CD19+
samples), INPP5F expression was identified as a prognostic factor
for PFS, regardless of adjusting for treatment, age, Binet stage,
IGVH mutational status, del(17p) and ECOG performance status
(mRNA term Po0.001; HR, 1.63; 95% CI, 1.35–1.98 without
adjustment; mRNA term Po0.001; HR, 1.48; 95% CI, 1.20–1.83
with adjustment),that were selected by a forward-stepwise
selection procedure among a larger set of prognostic factors
(see Statistical Analysis section). The treatment–mRNA interaction
term was not significant in either case (P= 0.31/0.24 without/with
adjustment), suggesting that INPP5F is a prognostic rather than
predictive marker. When patients were dichotomized into low and
high INPP5F expression (based on the median expression level of
INPP5F), lower INPP5F expression was associated with improved
PFS (median PFS, 30.6 months) compared with higher INPP5F
expression (median PFS, 18.5 months, Figure 1a).
The prognostic value of INPP5F expression on PFS was
confirmed in the validation set (PBMC samples) with the mRNA
term Po0.001 in a Cox regression model regardless of adjusting
for age, Binet stage, IGVH mutational status, del(17p) and ECOG
performance status (HR, 1.73; 95% CI, 1.33–2.24 without adjust-
ment; HR, 1.83; 95% CI, 1.3–2.6 with adjustment). Again, the
treatment–mRNA interaction term was not significant (P= 0.9/0.9
without/with adjustment). The Kaplan–Meier curves for patients
grouped into low and high INPP5F expression based on the
median expression level are shown in Figure 1b (median PFS, 33
vs 17.6 months, respectively).
In addition to INPP5F, the only other genes that demonstrated
prognostic relevance for both PFS and OS with respect to
expression levels after adjustment of prognostic markers were
PDE8A (PFS: discovery set HR, 0.63; 95% CI, 0.47–0.84; Po0.001;
validation set HR, 0.54; 95% CI, 0.35–0.84; P= 0.0058; OS: discovery
set HR, 0.63; 95% CI, 0.45–0.89; P= 0.008; validation set HR, 0.51;
95% CI, 0.29–0.91; P= 0.021) and to a lesser extent MZB-1 (PFS:
discovery set HR, 1.46; 95% CI, 1.18–1.81; Po0.001, validation set
HR, 1.27; 95% CI, 0.97–1.66; P= 0.085; OS: discovery set HR, 1.38;
95% CI, 1.07–1.79; P= 0.014, validation set HR, 1.32; 95% CI, 0.92–
1.89; P= 0.14). The prognostic relevance of expression levels of
PDE8A and MZB-1 in CLL has been reported previously.9,10
INPP5F expression and OS
In addition, a Cox regression analysis was used to assess the
prognostic influence of INPP5F expression on OS. In the discovery
set (CD19+), INPP5F expression was significantly associated with
OS in a univariate model (Po0.001; HR, 1.47; 95% CI, 1.18–1.84)
as well as in a multivariate model (P= 0.013; HR, 1.36; 95%
CI, 1.07–1.73) adjusted for treatment, age, IGVH mutational status,
del(17p), β-microglobulin and ECOG performance status that were
selected by a forward-stepwise selection procedure among a
larger set of prognostic factors (see Statistical Analysis section).
Again, these findings were confirmed in the validation set (PBMCs)
with Po0.001 (HR, 1.82; 95% CI, 1.32–2.51) in univariate analysis
and P= 0.011 (HR, 1.75; 95% CI, 1.14–2.7) in multivariate analysis.
The treatment–mRNA interaction term was not significant in
either case (P= 0.78/0.5 and P= 0.86/0.98, respectively, for CD19+
and PBMC without/with adjustment). The Kaplan–Meier curves of
OS for patients grouped into low and high INPP5F expression are
provided in Figures 2a and b, respectively, for the CD19+ and
PBMC data set.
In addition, INPP5F expression measured by Affymetrix HG-U133
Plus 2.0 microarray from a set of 107 patients with newly
diagnosed CLL9 available in the Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/; experiment-ID = E-
GEOD-22762) was analyzed for OS. In this additional, independent
data set, a significant correlation between OS and INPP5F
(P= 0.006; HR, 2.0; 95% CI, 1.2–3.3) was again observed in a
univariate Cox regression analysis. INPP5F remained significant
(P= 0.02; HR, 1.7; 95% CI, 1.1–2.7) after adjusting for del(17p) and
trisomy 12 (a stepwise variable selection did exclude del(11q) and
del(13q) from the model; no other predictors were made publicly
available). The Kaplan–Meier curves of OS for patients grouped
into low and high INPP5F expression are provided in Figure 3.
Correlation of INPP5F expression to BCL-2, IKKβ (IKKb)
and IKBα (IKBa)
In the discovery set (CD19+), there was a significant correlation of
INPP5F expression to the expression level of BCL-2 (r= 0.4;
Po0.001). A trend toward statistical significance was observed
when INPP5F and BCL-2 expression were correlated in the
Figure 1. The mRNA isolated from: (a) CD19+-separated samples and
(b) PBMCs. Kaplan–Meier curves of PFS stratified by INPP5F
expression levels (red: high INPP5F expression, above the median;
blue: low INPP5F expression, below the median).
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validation set (PBMCs: r= 0.20; P= 0.06). IKKb gene expression was
found to be significantly correlated to INPP5F gene expression in
the discovery set (CD19+: r= 0.45; Po0.001) as well as in the
validation set (PBMCs: r= 0.32; P= 0.0015). There was an inverse
correlation of INPP5F gene expression to IKBa gene expression in
both the discovery set (CD19+: r= –0.26; Po0.001) and the
validation set (PBMCs: r= –0.29; Po0.001). The expression of
INPP5F was correlated to the expression of other genes involved in
the nuclear factor (NF)-κB signaling cascade (see Supplementary
Figures 1a–l and Supplementary Table 1).
DISCUSSION
INPP5F is one of the several polyphosphoinositide phosphatases
whose role has been partially elucidated.11 INPP5F degrades PIP2
(phosphatidylinositol 4,5-bisphosphonate) and PIP3 (phosphatidy-
linositol 3,4,5-trisphosphonate) regulating AKT/phosphatidylinosi-
tol 3-kinase (PI3K) signaling.12–15 INPP5F is predicted to reduce
PIP3 levels and subsequently reduce AKT/PI3K signaling, thereby
attenuating expression of antiapoptotic molecules and leading to
increased chemotherapy sensitivity. Because of this, our data
showing that lower INPP5F levels are associated with improved
outcome and higher INPP5F levels with poorer outcome in CLL
may seem contradictory. However, it has been demonstrated
that INPP5F acts as a regulator of PIP3 levels. Stimulation of the
AKT/PI3K pathway with insulin-like growth factor in INPP5F
knockout mice led to a substantial increase in PIP3 levels
compared with INPP5F wild-type mice,16 suggesting a feedback
loop of INPP5F when the ATK/PI3K pathway is stimulated. In
addition, unlike PTEN, which degrades PIP3 to PI(4,5)P2, INPP5F
degrades PIP3 to PI(3,4)P2, which can function as a second
messenger. Furthermore, PI(3,4)P2 activity has been shown to
correlate with AKT activity.15
In CLL, the NF-κB signaling pathway has been shown to be
constitutively active,17 resulting in downstream overexpression of
antiapoptotic BCL-2 family members.18,19 BCL-2 and BCL-2 family
members have been shown to be upregulated in CLL and are also
shown to be associated with an unfavorable prognosis20–27 and
the connection between BCL-2 and NF-κB has been reported for
various hematological malignancies including CLL.17,28
Rituximab has been shown to exert its antitumor activity in vitro
by attenuating constitutively active AKT and subsequent modula-
tion expression of the antiapoptotic proteins of the BCL-2
family.29,30 Moreover, this rituximab-mediated downregulation of
active AKT resulted in sensitization to chemotherapeutics. Low
levels of BCLxl have been shown to be associated with sensitivity
to chemotherapy and CD20-targeted therapy.29 In addition,
increased levels of BCL-2 family protein have been associated
with poorer response to fludarabine and a shorter time to first
treatment interval.23 We also detected significant correlation of
INPP5F expression with gene expression of BCL-2 (r= 0.4;
Po0.001) and a significant correlation of INPP5F to IKKb
expression (r= 0.45; Po0.001), whereas for the expression levels
of IKBa, a significant inverse correlation to the expression of
INPP5F was observed (r= –0.26; Po0.001). Interestingly, the
INPP5F expression level correlated significantly with the expres-
sion of IKKb/IKBKB, an activator of NF-κB, and was inversely
correlated to expression of IKBa, an inhibitor of NF-κB,31,32
suggesting an association between high expression of INPP5F
and the activated NF-κB pathway and an agonistic AKT/PI3K
function. However, none of the latter genes demonstrated
significant prognostic relevance in the present study.
Figure 2. The mRNA isolated from: (a) CD19+-separated samples and
(b) PBMCs. Kaplan–Meier curves of OS stratified by INPP5F
expression levels (red: high INPP5F expression, above the median;
blue: low INPP5F expression, below the median).
Figure 3. Data set from Herold et al.9 Kaplan–Meier curves of OS
stratified by INPP5F expression levels (red: high INPP5F expression,
above the median; blue: low INPP5F expression, below the
median).
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To our knowledge, this is the first study describing INPP5F
expression level as a novel prognostic biomarker for PFS as well as
OS in a large set of patients treated within a randomized trial. Its
prognostic relevance was found in a set of CD19-enriched PBMC
samples, and subsequently confirmed in a validation set of
unselected PBMCs. The robustness of gene expression profiling for
biomarker research in peripheral blood has been demonstrated in
multiple previous reports, showing a significant correlation of
expression levels between array-based gene expression analysis
and reverse transcription-PCR, such as the MAQC Consortium33
and also previous publication of outcomes with this same set of
samples.5,34 Along these lines, Herold et al.9,10 showed significant
correlation of MZB-1 expression in CLL samples when comparing
array-based expression profiling with reverse transcription-PCR. In
addition, MZB-1 showed significant correlation to the expression
of INPP5F, a result that could be confirmed in our discovery set
(r= 0.44, Po0.001; Supplementary Materials) and validation set
(r= 0.36, Po0.001; Supplementary Materials), further emphasizing
the robustness of the reported array data. Further evidence of the
prognostic relevance of INPP5F levels stems from a subset of
untreated (first-line) CLL patients, in whom high expression levels
of INPP5F mRNA were associated with resistance to R-FC and FC
therapy,35 as well as a set of previously treated and untreated CLL
patients9 showing that INPP5F expression levels were an adverse
prognostic factor for OS. Further research is warranted to
understand the biological function of INPP5F on survival signaling.
INPP5F may be a novel, easily assessable biomarker in CLL,
because its prognostic significance of INPP5F expression remained
detectable in the set of unselected PBMCs, and this may support
the clinical feasibility of this biomarker as the analytical workflow
may not require separation of B cells as for ZAP70 or laborious
assessment of the IGVH mutational status. To determine the
significance of INPP5F for prognostic and therapeutic decision
making, INPP5F cutoff levels need to be defined, and the
prognostic relevance of INPP5F expression needs to be analyzed
in the context of other therapies used for treatment of CLL such as
bendamustine.36,37 In addition, our data may also support the
strategy of combining NF-κB and/or BCL-2 inhibitors to standard
therapy in CLL.
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